MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry
March 25, 2024 07:48 ET
|
MetasTx LLC
Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
December 21, 2023 16:00 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET
|
Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
October 03, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
July 24, 2023 07:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
July 10, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...